全球醫藥原料藥/合約研發生產機構市場規模、佔有率、趨勢及成長分析報告（2026-2034）

原料藥(API) 的合約開發和生產 (CDMO) 市場預計將從 2025 年的 978.7 億美元成長到 2034 年的 1904.9 億美元，2026 年至 2034 年的複合年成長率為 7.68%。

受製藥公司外包需求增加的推動，全球原料藥（原料藥）和合約研發生產機構（CDMO）市場正經歷強勁成長。 CDMO在原料藥開發、規模化生產和商業化生產方面提供專業知識。藥物研發活動的活性化以及對具成本效益生產解決方案日益成長的需求正在推動市場擴張。

關鍵成長要素包括藥物分子日益複雜化、生物製藥生產規模擴大以及監管合規要求日益嚴格。製藥公司擴大與合約研發生產機構（CDMO）合作，以縮短產品上市時間並最佳化營運成本。此外，對學名藥和專科藥物生產投資的增加也支撐了市場需求。

隨著人們對個人化醫療和高活性原料藥的關注度不斷提高，市場前景依然樂觀。新興市場生產設施的擴張帶來了巨大的成長機會。製程最佳化和品管方面的持續創新將增強市場競爭力。隨著全球醫藥研發的持續成長，原料藥合約研發生產（API CDMO）市場預計將維持長期穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球藥品原料藥/ CDMO市場：依產品分類

• 市場分析、洞察與預測
• 傳統藥物原料藥（API）
• 高效活性原料藥（HP-APIs）
• 抗體藥物複合體（ADC）
• 其他

第5章：全球原料藥CDMO市場：依合成方式分類

• 市場分析、洞察與預測
• 合成
• 生物技術

第6章 全球藥品原料藥CDMO市場：依藥物類型分類

• 市場分析、洞察與預測
• 創新的
• 學名藥

第7章 全球原料藥CDMO市場：依工作流程分類

• 市場分析、洞察與預測
• 臨床
• 商業的

第8章 全球醫藥原料藥/ CDMO市場：依應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 荷爾蒙藥物
• 青光眼
• 心血管疾病
• 糖尿病
• 其他

第9章 全球醫藥原料藥/ CDMO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Cambrex Corporation
  • Recipharm AB
  • Thermo Fisher Scientific Inc.（Pantheon）
  • CordenPharma International
  • Samsung Biologics
  • Lonza
  • Catalent Inc
  • Siegfried Holding AG
  • Piramal Pharma Solutions
  • Boehringer Ingelheim International GmbH

The Active Pharmaceutical Ingredient CDMO Market size is expected to reach USD 190.49 Billion in 2034 from USD 97.87 Billion (2025) growing at a CAGR of 7.68% during 2026-2034.

The Global Active Pharmaceutical Ingredient CDMO Market is experiencing strong growth due to increasing outsourcing by pharmaceutical companies. Contract development and manufacturing organizations (CDMOs) provide specialized expertise in API development, scale-up, and commercial production. Rising drug development activities and growing demand for cost-efficient manufacturing solutions are driving market expansion.

Major growth drivers include increasing complexity of drug molecules, expansion of biologics production, and regulatory compliance requirements. Pharmaceutical companies are partnering with CDMOs to accelerate time-to-market and optimize operational costs. Additionally, growing investment in generic and specialty drug manufacturing supports demand.

Future prospects remain positive with rising focus on personalized medicine and high-potency APIs. Expansion of manufacturing facilities in emerging markets offers significant growth opportunities. Continuous innovation in process optimization and quality control will strengthen market competitiveness. As pharmaceutical R&D continues to grow globally, the API CDMO market is expected to maintain steady long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Traditional Active Pharmaceutical Ingredient (Traditional API)
• Highly Potent Active Pharmaceutical Ingredient (HP-API)
• Antibody Drug Conjugate (ADC)
• Others

By Synthesis

• Synthetic
• Biotech

By Drug

• Innovative
• Generics

By Workflow

• Clinical
• Commercial

By Application

• Oncology
• Hormonal
• Glaucoma
• Cardiovascular Disease
• Diabetes
• Others

COMPANIES PROFILED

• Cambrex Corporation, Recipharm AB, Thermo Fisher Scientific Inc Pantheon, CordenPharma International, Samsung Biologics, Lonza, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim International GmbH
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Traditional Active Pharmaceutical Ingredient (Traditional API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antibody Drug Conjugate (ADC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY SYNTHESIS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Synthesis
• 5.2. Synthetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biotech Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY DRUG 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug
• 6.2. Innovative Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Workflow
• 7.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Application
• 8.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Hormonal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product
  • 9.2.2 By Synthesis
  • 9.2.3 By Drug
  • 9.2.4 By Workflow
  • 9.2.5 By Application
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product
  • 9.3.2 By Synthesis
  • 9.3.3 By Drug
  • 9.3.4 By Workflow
  • 9.3.5 By Application
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product
  • 9.4.2 By Synthesis
  • 9.4.3 By Drug
  • 9.4.4 By Workflow
  • 9.4.5 By Application
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product
  • 9.5.2 By Synthesis
  • 9.5.3 By Drug
  • 9.5.4 By Workflow
  • 9.5.5 By Application
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product
  • 9.6.2 By Synthesis
  • 9.6.3 By Drug
  • 9.6.4 By Workflow
  • 9.6.5 By Application
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Cambrex Corporation
  • 11.2.2 Recipharm AB
  • 11.2.3 Thermo Fisher Scientific Inc. (Pantheon)
  • 11.2.4 CordenPharma International
  • 11.2.5 Samsung Biologics
  • 11.2.6 Lonza
  • 11.2.7 Catalent Inc
  • 11.2.8 Siegfried Holding AG
  • 11.2.9 Piramal Pharma Solutions
  • 11.2.10 Boehringer Ingelheim International GmbH